Organon & Co: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Organon & Co Unternehmen

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Organon & Co Informationen



BörsenkürzelOGN

Name des UnternehmensOrganon & Co

IPO-datumMay 14, 2021

CEOMorrissey (Joseph T)

Anzahl der mitarbeiter10000

WertpapierartOrdinary Share

GeschäftsjahresendeMay 14

Addresse30 Hudson Street

StadtJERSEY CITY

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl07302

Telefon15514306000

Websitehttps://www.organon.com/

BörsenkürzelOGN

IPO-datumMay 14, 2021

CEOMorrissey (Joseph T)

Führungskräfte von Organon & Co



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

144.48K

+11400.00%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

71.89K

+11117.00%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

59.92K

+5500.00%

Mr. Kirke Weaver

Executive Vice President, General Counsel, Corporate Secretary

52.85K

+8045.00%

Mr. Vittorio Nisita

Executive Vice President, Head of Enterprise Services & Solutions

41.33K

+8698.00%

Ms. Rochelle B. (Shelly) Lazarus

Independent Director

633.00

--

Ms. Shalini Sharp

Independent Director

2.00

--

Mr. Robert A. (Bob) Essner

Lead Independent Director

--

Ms. Cynthia M. Patton

Independent Director

--

Ms. Grace M. Puma Whiteford

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

144.48K

+11400.00%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

71.89K

+11117.00%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

59.92K

+5500.00%

Mr. Kirke Weaver

Executive Vice President, General Counsel, Corporate Secretary

52.85K

+8045.00%

Mr. Vittorio Nisita

Executive Vice President, Head of Enterprise Services & Solutions

41.33K

+8698.00%

Ms. Rochelle B. (Shelly) Lazarus

Independent Director

633.00

--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Women’s Health

429.00M

26.78%

Cardiovascular

307.00M

19.16%

Non-Opioid Pain, Bone and Dermatology

266.00M

16.60%

Other

220.00M

13.73%

Biosimilars

196.00M

12.23%

Respiratory

184.00M

11.49%

Nach RegionUSD

Name

Umsatz

Anteil

Europe and Canada

417.00M

26.03%

United States

406.00M

25.34%

Latin America, Middle East, Russia and Africa

286.00M

17.85%

Asia Pacific and Japan

251.00M

15.67%

China

219.00M

13.67%

Other

23.00M

1.44%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Women’s Health

429.00M

26.78%

Cardiovascular

307.00M

19.16%

Non-Opioid Pain, Bone and Dermatology

266.00M

16.60%

Other

220.00M

13.73%

Biosimilars

196.00M

12.23%

Respiratory

184.00M

11.49%

Aktionärsstatistik

Aktualisiert: Sat, Jan 10

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

14.13%

BlackRock Institutional Trust Company, N.A.

10.68%

State Street Investment Management (US)

3.59%

LSV Asset Management

2.87%

MFS Investment Management

2.65%

Andere

66.09%

Aktionäre

Anteil

The Vanguard Group, Inc.

14.13%

BlackRock Institutional Trust Company, N.A.

10.68%

State Street Investment Management (US)

3.59%

LSV Asset Management

2.87%

MFS Investment Management

2.65%

Andere

66.09%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

46.15%

Investment Advisor/Hedge Fund

19.85%

Hedge Fund

4.73%

Pension Fund

2.55%

Research Firm

2.05%

Sovereign Wealth Fund

0.86%

Bank and Trust

0.82%

Individual Investor

0.36%

Venture Capital

0.04%

Andere

22.59%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

1386

201.61M

77.55%

-50.44M

2025Q3

1485

219.88M

84.58%

-37.41M

2025Q2

1527

205.34M

78.98%

-50.49M

2025Q1

1611

213.21M

82.04%

-52.34M

2024Q4

1647

218.39M

84.67%

-40.43M

2024Q3

1625

211.80M

82.26%

-47.57M

2024Q2

1676

208.67M

81.14%

-51.47M

2024Q1

1700

205.29M

80.30%

-45.21M

2023Q4

1767

202.90M

79.38%

-24.07M

2023Q3

1835

205.61M

80.45%

-25.35M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

35.78M

13.76%

+3.64M

+11.31%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

27.75M

10.68%

-529.65K

-1.87%

Sep 30, 2025

State Street Investment Management (US)

9.34M

3.59%

-185.02K

-1.94%

Sep 30, 2025

LSV Asset Management

7.83M

3.01%

-154.92K

-1.94%

Sep 30, 2025

MFS Investment Management

9.43M

3.63%

-674.26K

-6.67%

Sep 30, 2025

Geode Capital Management, L.L.C.

4.82M

1.85%

+419.78K

+9.55%

Sep 30, 2025

Millennium Management LLC

4.53M

1.74%

-4.56M

-50.19%

Sep 30, 2025

UBS Financial Services, Inc.

2.73M

1.05%

-3.19M

-53.87%

Sep 30, 2025

AQR Capital Management, LLC

4.18M

1.61%

+921.26K

+28.30%

Sep 30, 2025

Gotham Asset Management, LLC

3.71M

1.43%

+1.01M

+37.25%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Tue, Dec 2

Name

Anteil

State Street SPDR S&P Pharmaceuticals ETF

1.72%

Alger Russell Innovation ETF

1.39%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.22%

First Trust Health Care Alphadex Fund

1.1%

Invesco S&P SmallCap Health Care ETF

1.07%

Brandes US Small-Mid Cap Value ETF

1.05%

iShares U.S. Pharmaceuticals ETF

0.65%

Lattice Hartford Multifactor Small Cap ETF

0.5%

WisdomTree U.S. SmallCap Dividend Fund

0.5%

Royce Quant Small-Cap Quality Value ETF

0.45%

State Street SPDR S&P Pharmaceuticals ETF

Anteil1.72%

Alger Russell Innovation ETF

Anteil1.39%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Anteil1.22%

First Trust Health Care Alphadex Fund

Anteil1.1%

Invesco S&P SmallCap Health Care ETF

Anteil1.07%

Brandes US Small-Mid Cap Value ETF

Anteil1.05%

iShares U.S. Pharmaceuticals ETF

Anteil0.65%

Lattice Hartford Multifactor Small Cap ETF

Anteil0.5%

WisdomTree U.S. SmallCap Dividend Fund

Anteil0.5%

Royce Quant Small-Cap Quality Value ETF

Anteil0.45%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 1.03B USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Nov 10, 2025

OGN.NB Final Cash Dividend of gross USD 0.02 paid on Dec 11, 2025 going ex on Nov 20, 2025

Nov 20, 2025

Dec 11, 2025

Nov 20, 2025

Aug 05, 2025

OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Sep 11, 2025 going ex on Aug 15, 2025

Aug 15, 2025

Sep 11, 2025

Aug 15, 2025

May 01, 2025

OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Jun 12, 2025 going ex on May 12, 2025

May 12, 2025

Jun 12, 2025

May 12, 2025

Feb 13, 2025

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025

Feb 24, 2025

Mar 13, 2025

Feb 24, 2025

Oct 31, 2024

OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024

Nov 12, 2024

Dec 12, 2024

Nov 12, 2024

Aug 06, 2024

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Sep 12, 2024

Aug 16, 2024

May 02, 2024

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024

May 13, 2024

Jun 13, 2024

May 10, 2024

Feb 15, 2024

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024

Feb 26, 2024

Mar 14, 2024

Feb 23, 2024

Nov 02, 2023

OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023

Nov 13, 2023

Dec 14, 2023

Nov 10, 2023

Aug 08, 2023

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Sep 14, 2023

Aug 17, 2023

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten